China’s Osteoporosis Guidelines Get a Middling Report Card in First Systematic Audit

China has the largest elderly population on Earth, and its bones are failing at a scale no other nation has ever confronted. According to the country’s 2021 national census, more than 264 million people—18.7 percent of the population—are over 60 years old, and those over 65 have surpassed 190 million. The China Development Research Foundation projects that aging will peak between 2035 and 2050, with roughly 380 million people, or about 30 percent of the population, aged 65 or older by 2050. Against that demographic backdrop, osteoporosis is not a niche concern but a slow-motion public health emergency, and the clinical practice guidelines meant to tame it have now been put under the microscope for the first time.

A team of researchers from Chongqing Medical University and Chongqing General Hospital has published the first systematic review to rigorously audit the quality of Chinese osteoporosis guidelines, appearing in Frontiers in Endocrinology. Led by Xiaonan Liu, Mengya Ge, and Shunxia Sun, the group scoured six Chinese sources—CNKI, SinoMed, Wanfang, VIP, Medlive, and the Chinese Medical Association website—for guidelines published between January 2014 and December 2025. After screening 576 publications down to 78 full texts and ultimately 13 eligible clinical practice guidelines, they subjected each to two of the most demanding appraisal instruments in modern medicine: AGREE II, which measures methodological rigor across six domains, and AGREE-REX, which probes whether the recommendations themselves are credible and implementable at the bedside.

The headline finding is sobering but nuanced. The median overall quality score across the 13 guidelines was just 54 percent, with an interquartile range of 49 to 71 percent. Only four guidelines scored above 50 percent in every AGREE II domain. The single weakest domain was rigor of development—the process of gathering, synthesizing, and grading evidence behind each recommendation—which scored a median of just 38 percent. That number hides enormous variability, though: the interquartile range stretched from 25 to 94 percent, meaning some guidelines were built on meticulous evidence pipelines while others essentially skipped that step entirely. At the other end, stakeholder involvement and clarity of presentation both scored a median of 72 percent, suggesting Chinese developers write clearly and assemble diverse expert panels but often fail to document how they arrived at their conclusions.

The pattern becomes sharper when you look at which guidelines used the GRADE system—the Grades of Recommendation, Assessment, Development, and Evaluation framework that has become the international gold standard for translating evidence into recommendation strength. Six of the 13 guidelines integrated GRADE; the other seven referenced no evidence-based grading system at all. The five GRADE-based guidelines from the Chinese Association of Gerontology and Geriatrics Osteoporosis Society, the Chinese Orthopaedic Association groups, the Chinese Rehabilitation Medicine Association, and a practice guideline by M.L. Qiu and colleagues all scored above 79 percent in rigor of development. The rehabilitation guideline from the Chinese Rehabilitation Medicine Association, developed with input from an evidence-based medicine center at Lanzhou University, earned the highest overall score of any guideline in the review: 95 percent. The lowest score, 35 percent, went to a 2018 guide by G.X. Qiu and colleagues that lacked a documented search strategy and update procedure.

Several specific gaps emerged with striking consistency. Nine of the 13 guidelines—69.2 percent—never mentioned monitoring or auditing criteria to track whether their recommendations actually change practice. Seven, or 53.8 percent, did not mention external expert review, a cornerstone of guideline credibility that scored a mean of just 29.7 percent across all documents. Five guidelines failed to disclose the financial interests of their development group members, and four did not describe the literature search strategy used to identify evidence. Seven explicitly acknowledged having no procedure for updating, which means the documents risk becoming stale as new fracture-prevention trials and drug classes emerge.

Ten guidelines met the review’s threshold—scoring at least 50 percent in three or more AGREE II domains—for the deeper AGREE-REX evaluation, which examines clinical applicability, values and preferences, and implementability. Their median overall recommendation quality score was 56 percent, and four guidelines scored below 30 percent in at least one domain. The weakest domain was values and preferences, with a median of 43 percent, reflecting how rarely developers documented whether they had consulted policy makers, patients, or the health system itself when weighing trade-offs. Eighty percent of the evaluated guidelines did not record whether the values of policy or decision makers had been considered at all—a striking omission in a country where osteoporosis is increasingly framed as a societal challenge requiring governmental investment, not merely a clinical problem for individual physicians.

Yet the review also found genuine strengths worth celebrating. The guidelines scored highest on items measuring whether development groups included all relevant professional groups, whether the target population was specifically described, whether recommendations were explicitly linked to supporting evidence, whether key recommendations were easy to identify, and whether the funding body’s views had not influenced content. The ten AGREE-REX-evaluated guidelines covered prevention, nutrition, exercise, psychological support, rehabilitation, and fall-risk reduction—territory that aligns closely with international benchmarks from the Scottish Intercollegiate Guidelines Network, the UK’s National Institute for Health and Care Excellence, the National Osteoporosis Guideline Group, and Osteoporosis Canada. Recommendations on functional assessment, calcium supplementation, diet, exercise, rehabilitation, and environmental modification were judged particularly valuable and directly applicable to Chinese patients.

One of the most intriguing findings concerns traditional Chinese medicine. Several guidelines incorporated TCM practices such as tai chi, qigong, Eight Section Brocade, and Five Animal Play, describing anticipated benefits including pain relief, improved muscle strength, and better gait stability. The authors note that these recommendations are culturally appropriate and may eventually serve as a reference for guideline developers in other countries—but because the underlying clinical evidence remains limited, the strength of these recommendations is typically rated as C, the lowest tier. The review’s authors are careful not to overclaim: they call for more rigorous trials to confirm the reliability of TCM-based exercise interventions before they can be exported as evidence-based practice.

The statistical architecture of the review reinforces its central message. Spearman correlation analysis revealed a positive correlation of r = 0.665 between AGREE II and AGREE-REX overall scores, meaning guidelines built with methodological care tend to produce more credible, implementable recommendations. Even more striking, the AGREE-REX overall score correlated strongly with the AGREE II rigor of development domain at r = 0.839, and the AGREE-REX clinical applicability domain correlated with rigor of development at r = 0.826. In plain terms: the rigor of the evidence-synthesis process is the single strongest predictor of whether a guideline’s recommendations will actually work in the real world. Guidelines that skip the hard methodological work tend to produce recommendations that clinicians cannot confidently apply.

The review has limitations the authors acknowledge candidly. Restricting the search to guidelines published from 2014 onward may have excluded earlier but still relevant documents. The threshold of three or more AGREE II domains scoring at least 50 percent for AGREE-REX evaluation may have omitted some methodologically sound guidelines. Guidelines focused on osteoporosis comorbidities were excluded, so the findings should not be read as a verdict on every Chinese osteoporosis guideline in existence. And critically, the study evaluated guideline quality but did not assess whether higher-quality guidelines actually lead to better clinical outcomes—a link that remains unproven and represents the next frontier for this research program.

Still, the implications are hard to ignore. With more than one million new hip fractures recorded in China each year and a projected 6.3 million hip fractures annually among older adults worldwide by 2050—more than half in Asia—the stakes of getting these guidelines right could not be higher. Awareness rates among Chinese patients aged 40 to 49 are just 0.9 percent, rising to only 7.0 percent among those over 50, meaning the gap between what guidelines recommend and what patients actually know is vast. The authors recommend that future developers adopt GRADE or equivalent evidence-grading systems, involve dedicated evidence-based medicine centers in the drafting process, and—perhaps most importantly—actively engage policy makers and decision makers so that recommendations are feasible within the broader healthcare system and can secure the public resources osteoporosis care desperately needs. For a country staring down the largest osteoporosis burden in human history, the blueprint for improvement is now written down. The question is whether the next generation of guidelines will follow it.

Subject of Research: Systematic appraisal of the methodological and recommendation quality of Chinese clinical practice guidelines for osteoporosis management using AGREE II and AGREE-REX

Article Title: Quality of osteoporosis management guidelines produced in China: a systematic review

Article References: Liu, X., Ge, M., Wu, C., Shen, K., Yang, J., & Sun, S. (2026). Quality of osteoporosis management guidelines produced in China: a systematic review. Frontiers in Endocrinology, 17, Article 1907308. https://doi.org/10.3389/fendo.2026.1907308

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1907308

Keywords: osteoporosis, clinical practice guidelines, AGREE II, AGREE-REX, GRADE system, China, systematic review, fragility fractures, traditional Chinese medicine, guideline quality, elderly health, evidence-based medicine